Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
44 stopped studies mapped to Malignant Nasopharyngeal Neoplasm and descendants · 89% state a reason
Over the 44 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05290194 | Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of… | Phase 2 | withdrawn | Mar 22, 2022 | Fifth Affiliated Hospital, Sun Yat-Sen University | The study was terminated because the protocol was upgraded after being considered insufficiently… | Other (stated, no rule matched) |
| NCT05904080 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug… | Phase 2 | suspended | Jun 15, 2023 | National Cancer Institute (NCI) | Scheduled Interim Monitoring | Other (stated, no rule matched) |
| NCT05198479 | Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in(SG-AAA-II-01) | Phase 2 | suspended | Jan 20, 2022 | National Cancer Centre, Singapore | Seeking further funding before resuming the study. | Funding |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)… | Phase 1 / Phase 2 | terminated | Feb 9, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1160 due to slow enrolment | Enrollment / accrual |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced… | Phase 1 / Phase 2 | terminated | Oct 7, 2021 | Takeda | Clinical Futility of TAK 500 met. No further development with this compound | Efficacy / futility |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced… | Phase 1 | terminated | May 9, 2017 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual… | Phase 3 | terminated | Jul 7, 2020 | National Cancer Institute (NCI) | External information | Other (stated, no rule matched) |
| NCT02363400 | A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA | Phase 3 | terminated | Feb 16, 2015 | National Health Research Institutes, Taiwan | Recruiting progress behind expectation | Enrollment / accrual |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With… | Phase 1 | terminated | Dec 22, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr… | Phase 1 / Phase 2 | terminated | Dec 7, 2018 | Atara Biotherapeutics | Phase 1B part was completed with review of DLTs and cumulative safety data by Safety Data Review… | Safety / toxicity |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT02875613 | Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer | Phase 2 | terminated | Aug 23, 2016 | Assuntina Sacco, M.D. | Slow patient accrual | Enrollment / accrual |
| NCT06189482 | Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for…(NPC) | N/A | terminated | Jan 3, 2024 | Zeng Changhao | ethical issues | Other (stated, no rule matched) |
| NCT06248840 | Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for… | N/A | terminated | Feb 8, 2024 | Zeng Changhao | ethical issues | Other (stated, no rule matched) |
| NCT03682055 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive… | Phase 1 / Phase 2 | terminated | Sep 24, 2018 | Cullinan Therapeutics Inc. | Lack of efficacy | Efficacy / futility |
| NCT02698111 | Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | terminated | Mar 3, 2016 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Corporate policy adjustments | Other (stated, no rule matched) |
| NCT03544099 | Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr… | Phase 2 | terminated | Jun 1, 2018 | National Health Research Institutes, Taiwan | Difficult to recruit Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA | Enrollment / accrual |
| NCT02582008 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With… | Early Phase 1 | terminated | Oct 21, 2015 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT02289807 | Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated… | N/A | withdrawn | Nov 13, 2014 | Sun Yat-sen University | not stated | Not stated |
| NCT03390738 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2… | Phase 2 | withdrawn | Jan 4, 2018 | The University of Hong Kong | Sponsor withdrew funding for Nivolumab | Funding |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic… | Phase 2 | withdrawn | Jan 18, 2020 | Alain Algazi | Feasibility | Other (stated, no rule matched) |
| NCT00181220 | Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal… | Phase 1 | withdrawn | Sep 16, 2005 | Johns Hopkins University | PI left JHU and is not able to be reached for updates | Investigator |
| NCT00367718 | Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma | Phase 2 | withdrawn | Aug 23, 2006 | Johns Hopkins University | PI left JHU and is not able to be reached for updates | Investigator |
| NCT02569788 | Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | terminated | Oct 7, 2015 | Shanghai Proton and Heavy Ion Center | Slow accrual of patients. | Enrollment / accrual |
| NCT02801487 | Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally… | Phase 1 / Phase 2 | terminated | Jun 15, 2016 | Shanghai Proton and Heavy Ion Center | Slow accrual of patients. | Enrollment / accrual |
| NCT01230476 | Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally… | Phase 2 | terminated | Oct 29, 2010 | University of Malaya | not stated | Not stated |
| NCT02789189 | Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic… | Phase 2 | terminated | Jun 2, 2016 | Sun Yat-sen University | not stated | Not stated |
| NCT02137096 | Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma | Phase 3 | terminated | May 13, 2014 | University of Florida | This is a rare disease, and enrollment was poor. | Enrollment / accrual |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | Phase 2 | terminated | Mar 11, 2016 | University of Chicago | Study stopped due to poor enrollment. | Enrollment / accrual |
| NCT00484601 | Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma | Phase 2 | terminated | Jun 11, 2007 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Low accrual. | Enrollment / accrual |
| NCT03049358 | Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With… | N/A | terminated | Feb 10, 2017 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT02388932 | Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced… | N/A | terminated | Mar 17, 2015 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT00828386 | Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers(NPC2006) | Phase 3 | terminated | Jan 23, 2009 | Groupe Oncologie Radiotherapie Tete et Cou | Low accrual | Enrollment / accrual |
| NCT02022293 | Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From… | Phase 2 | suspended | Dec 27, 2013 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Enrollment target could not be achieved. | Enrollment / accrual |
| NCT00797290 | Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx(NP01) | — | terminated | Nov 25, 2008 | University of Florida | Slow enrollment, Feasibility issues | Enrollment / accrual |
| NCT02080416 | Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors | Early Phase 1 | terminated | Mar 6, 2014 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Very slow accrual; terminated to allow resources to be utilized more effectively on other studies.… | Enrollment / accrual |
| NCT02058017 | OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive… | Phase 1 | terminated | Feb 7, 2014 | National University Hospital, Singapore | Lactic and metabolic acidosis of OPB-51602 is not tolerable | Other (stated, no rule matched) |
| NCT01694576 | NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent… | Phase 2 | terminated | Sep 27, 2012 | Jiangsu Cancer Institute & Hospital | slow patient enrollment | Enrollment / accrual |
| NCT01254734 | Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck… | N/A | terminated | Dec 7, 2010 | City of Hope Medical Center | The study will be rewritten as a data registry study | Other (stated, no rule matched) |
| NCT01403259 | SOX as Salvage Treatment in Nasopharyngeal Carcinoma | Phase 2 | terminated | Jul 27, 2011 | Fudan University | poor accrual of eligible patients | Enrollment / accrual |
| NCT00515957 | Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)(DELLA) | Phase 1 | withdrawn | Aug 14, 2007 | Baylor College of Medicine | not stated | Not stated |
| NCT00201344 | A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage… | Phase 3 | terminated | Sep 20, 2005 | National Health Research Institutes, Taiwan | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials